Botond Roska and José-Alain Sahel have been awarded the Wolf Prize
(https://www.youtube.com/watch?v=czt6Pc56Ubk) in Medicine for their pioneering
work on restoring vision to blind patients using optogenetic therapy.
The Wolf Prize, considered one of the most prestigious international awards,
recognizes outstanding achievements in various fields including medicine.
Roska, Director at the Institute of Molecular and Clinical Ophthalmology Basel
(IOB) and Professor at the University of Basel, and Sahel, Chair of
Ophthalmology at the University of Pittsburgh School of Medicine and Chair of
IOB's Scientific Advisory Board, have collaborated since 2001. Their work
focuses on optogenetic vision restoration, a technique that creates light-
sensitive cells using genes derived from algae, to treat degenerative retinal
diseases.
In 2021, they reported groundbreaking results from an early-stage clinical trial
with blind retinitis pigmentosa patients. One patient who completed the full
study protocol was able to detect and move objects placed before him within
months of treatment. This work, which was done in collaboration with researchers
from the Institut de la Vision in Paris, marked the first proof-of-concept for
optogenetics in human disease. Despite initial scepticism, Roska and Sahel
persevered, recognizing the potential of optogenetics for treating retinal
diseases due to its mutation-independent approach and the accessibility of the
eye's optical system.
The collaboration between Roska, a basic scientist with an MD, and Sahel, an
accomplished clinician and expert in translational research, has proven highly
complementary. Their work represents a significant milestone in treating
blinding conditions affecting millions worldwide, with promising results
emerging from ongoing clinical trials. The Wolf Prize in Medicine acknowledges
their exceptional contributions to the field of ophthalmology.
About IOB
At the Institute of Molecular and Clinical Ophthalmology Basel (IOB), basic
researchers and clinicians work hand in hand to advance the understanding of
vision and its diseases, and to develop new therapies for vision loss. IOB
started its operations in 2018. The institute is constituted as a foundation,
granting academic freedom to its scientists. Founding partners are the
University Hospital Basel, the University of Basel and Novartis. The Canton of
Basel-Stadt has granted the institute substantial financial support.
Â